Education
About Us
Working with TipRanks
Follow Us
Amgen Inc (AMGN)
NASDAQ:AMGN
AMGN Stock Chart & Stats
$366.20
-$0.21(-0.08%)
At close: 4:00 PM EST
$366.20
-$0.21(-0.08%)
Day’s Range― - ―
52-Week Range$261.43 - $368.75
Previous CloseN/A
Volume614.18K
Average Volume (3M)2.25M
Market Cap
$197.19B
Enterprise Value$242.67B
Total Cash (Recent Filing)$9.13B
Total Debt (Recent Filing)$54.60B
Price to Earnings (P/E)23.8
Beta0.38
Next Earnings
Apr 29, 2026EPS Estimate
4.83Next Dividend Ex-DateN/A
Dividend Yield3%
Share Statistics
EPS (TTM)5.29
Shares Outstanding538,480,650
10 Day Avg. Volume2,954,847
30 Day Avg. Volume2,246,383
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)20.34
Price to Sales (P/S)4.79
P/FCF Ratio21.74
Enterprise Value/Market Cap1.23
Enterprise Value/Revenue6.61
Enterprise Value/Gross Profit9.37
Enterprise Value/Ebitda14.20
Forecast
1Y Price Target
$361.94Price Target Upside-1.16% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering22
EPS Forecast (FY)22.13
Revenue Forecast (FY)$37.19B
Bulls Say, Bears Say
Bulls Say
Earnings PerformanceEarnings that beat revenue and profit expectations point to stronger-than-expected commercial performance across multiple franchises, supporting confidence in near-term revenue resilience.
Repatha Market AccessBroad formulary coverage and an indication that includes both primary and secondary cardiovascular event prevention support sustained Repatha volume growth and a differentiated position among cholesterol therapies.
Uplizna Rare Disease PositioningUplizna's twice-yearly dosing and unique mechanism targeting CD19 B cells make it well positioned for adoption in IgG4-related disease and generalized myasthenia gravis, offering upside from expanding rare disease use.
Bears Say
Loss Of Exclusivity And Biosimilar CompetitionProjected loss of exclusivity for several major drugs and the arrival of aflibercept biosimilars create material revenue risk through market share erosion for established products.
MariTide Clinical UncertaintyUncertainty about MariTide's efficacy and tolerability, including nausea and vomiting concerns, could limit its competitive prospects in the obesity market without clear clinical differentiation.
Pipeline Setbacks And Regulatory RiskLate-stage program disruptions, including termination of a co-development and regulatory inquiries for marketed medicines, raise questions about near-term pipeline reliability and development momentum.
Amgen News
AMGN FAQ
What was Amgen Inc’s price range in the past 12 months?
Amgen Inc lowest stock price was $261.43 and its highest was $368.75 in the past 12 months.
What is Amgen Inc’s market cap?
Amgen Inc’s market cap is $197.19B.
When is Amgen Inc’s upcoming earnings report date?
Amgen Inc’s upcoming earnings report date is Apr 29, 2026 which is in 83 days.
How were Amgen Inc’s earnings last quarter?
Amgen Inc released its earnings results on Feb 03, 2026. The company reported $5.29 earnings per share for the quarter, beating the consensus estimate of $4.734 by $0.556.
Is Amgen Inc overvalued?
According to Wall Street analysts Amgen Inc’s price is currently Overvalued.
Does Amgen Inc pay dividends?
Amgen Inc pays a Quarterly dividend of $2.38 which represents an annual dividend yield of 3%. See more information on Amgen Inc dividends here
What is Amgen Inc’s EPS estimate?
Amgen Inc’s EPS estimate is 4.83.
How many shares outstanding does Amgen Inc have?
Amgen Inc has 538,480,650 shares outstanding.
What happened to Amgen Inc’s price movement after its last earnings report?
Amgen Inc reported an EPS of $5.29 in its last earnings report, beating expectations of $4.734. Following the earnings report the stock price went up 8.154%.
Which hedge fund is a major shareholder of Amgen Inc?
Currently, no hedge funds are holding shares in AMGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Amgen Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$361.94 (-1.16% Downside)
$361.94 (-1.16% Downside)
Blogger Sentiment
Bullish
AMGN Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 579.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.1%
Last 30 Days ▲ 0.2%
Last 30 Days ▲ 0.2%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
30.82%
12-Months-Change
Fundamentals
Return on Equity
106.10%
Trailing 12-Months
Asset Growth
-1.36%
Trailing 12-Months
Company Description
Amgen Inc
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
AMGN Company Deck
AMGN Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized broad, multi-product commercial momentum, strong financial performance, substantial R&D investment, and encouraging late-stage pipeline progress (notably Repatha, Meritide, biosimilars, rare disease approvals, and Imdeltra). Key challenges include a significant regulatory action on Tavneos, slower-than-expected event accrual for the olpasiran outcome study, several program deprioritizations, and anticipated near-term sales pressure from biosimilars/generics and seasonal/inventory headwinds. On balance, the positives — sustained growth across multiple franchises, clear 2026 guidance range, and a deep late-stage pipeline — outweigh the notable but addressable setbacks.View all AMGN earnings summariesAMGN Revenue Breakdown
13.09% Prolia
9.92% Enbrel
6.66% XGEVA
6.65% Repatha
63.69% Other
AMGN Stock 12 Month Forecast
Average Price Target
$361.94
▼(-1.16% Downside)
Technical Analysis
Ownership Overview
0.19% Insiders
24.37% Mutual Funds
0.37% Other Institutional Investors
45.86% Public Companies and Individual Investors